ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions
View by Date

Monday, October 22, 2018

9:00AM-11:00AM
Abstract Number: 1779
Is the Number of IgG4+ Plasma Cells Observed By Immunostaining Important Beyond Its Diagnostic Utility in IgG4-Related Disease?
Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease
9:00AM-11:00AM
Abstract Number: 1401
Is There a Specific Effect of Jak-Inhibitors on Pain and Fatigue in Rheumatoid Arthritis?
Patient Outcomes, Preferences, and Attitudes Poster I: Patient-Reported Outcomes
9:00AM-11:00AM
Abstract Number: 1235
Isoniazid Monotherapy As a Prophylaxis for Tuberculosis in Patients with Rheumatic Diseases Exposed to Prolonged, High-Dose Glucocorticoids
Infection-related Rheumatic Disease Poster
9:00AM-11:00AM
Abstract Number: 1397
Item Responses to Disease-Specific Quality of Life Questionnaires in the 18 Months Following a Flare in SLE: An Item Response Theory Analysis of a French Prospective Longitudinal Multicenter Study
Patient Outcomes, Preferences, and Attitudes Poster I: Patient-Reported Outcomes
9:00AM-11:00AM
Abstract Number: 1315
Japanese Relapsing Polychondritis Patients with Airway Involvement Were Mutually Exclusive with Those with Ear Involvement in the Clinical Characteristics
Miscellaneous Rheumatic and Inflammatory Diseases Poster II: Interstitial Lung Disease, Still's Disease, FMF, Polychondritis
9:00AM-11:00AM
Abstract Number: 1768
Kidney Involvement, Poor Performance Status, and Higher Cumulative Dose of Glucocorticoid Are the Risk Factors of the Discontinuation of Immunosuppressant in Patients with Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Vasculitis – ANCA-Associated Poster I
9:00AM-11:00AM
Abstract Number: 1431
Kikuchi-Fujimoto Disease: A Retrospective Analysis of 23 Pediatric Cases from a US Center
Pediatric Rheumatology – Clinical Poster II: Autoinflammatory Disorders, Scleroderma, and Miscellaneous
9:00AM-11:00AM
Abstract Number: 1377
Knee Osteoarthritis Symptom Duration Is Associated with Conditioned Pain Modulation and Vibration Perception Threshold Impairment
Osteoarthritis – Clinical Poster II
9:00AM-11:00AM
Abstract Number: 1671
Laboratory Investigation Results Influence Physician’s Global Assessment of Disease Activity in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes
9:00AM-11:00AM
Abstract Number: 1270
Lack of Association of Comorbidities with Ultrasonographic Urate Deposition in Asymptomatic Hyperuricemia
Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I
9:00AM-11:00AM
Abstract Number: 1581
Lack of Specificity in Testing for Murine Tissue Specific Autoantibodies for the Diagnosis of Sjogren’s Syndrome
Sjögren's Syndrome – Basic and Clinical Science Poster
9:00AM-11:00AM
Abstract Number: 1562
Large Granular Lymphocyte Proliferations in Primary Sjögren’s Syndrome: An Iatrogenic Manifestation
Sjögren's Syndrome – Basic and Clinical Science Poster
9:00AM-11:00AM
Abstract Number: 1620
Lateral DXA More Effective in Detecting Osteoporosis Than Conventional DXA in Axial Spondyloarthropathy
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies
9:00AM-11:00AM
Abstract Number: 1798
Leg Ulcers in Behçet’s Syndrome: An Observational Survey in 24 Patients
Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease
9:00AM-11:00AM
Abstract Number: 1454
Levels of 14-3-3eta Are an Independent Predictor of Long-Term Radiographic Erosive Progression and of Short-Term Rapid Radiographic Erosive Progression in Patients with Inflammatory Polyarthritis
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis
  • «Previous Page
  • 1
  • …
  • 28
  • 29
  • 30
  • 31
  • 32
  • …
  • 65
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology